Abstract
Despite advances in the decade in the teatment of patients with acute channel blockers interst in potassium channel blockrs has gained momentum. Amiodarone, in particular, has been the locus of much controversy. It is suggestd in cllnical trials to date that amiodarone may be benerical in patients afte myocardial intarction. It crtainly does not seem to be harmful. The answer to whether or not amiodarone will improve survival in post-myocardial intarction patients is the subject of two very important clinical trials the Canadion Amiedarone Myocardial intanction Trial and the Europan Myocardial Amiodarone Trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
